Discovery of (1R,5S)-N-[3-Amino-1-(cyclobutylmethyl)-2,3-dioxopropyl]- 3-[2(S)-[[[(1,1-dimethylethyl)amino]carbonyl]amino]-3,3-dimethyl-1-oxobutyl]- 6,6-dimethyl-3-azabicyclo[3.1.0]hexan-2(S)-carboxamide (SCH 503034), a Selective, Potent, Orally Bioavailable Hepatitis C Virus NS3 Protease Inhibitor: A Potential Therapeutic Agent for the Treatment of Hepatitis C Infection-Reference-Cited by-同舟云学术

Discovery of (1R,5S)-N-[3-Amino-1-(cyclobutylmethyl)-2,3-dioxopropyl]- 3-[2(S)-[[[(1,1-dimethylethyl)amino]carbonyl]amino]-3,3-dimethyl-1-oxobutyl]- 6,6-dimethyl-3-azabicyclo[3.1.0]hexan-2(S)-carboxamide (SCH 503034), a Selective, Potent, Orally Bioavailable Hepatitis C Virus NS3 Protease Inhibitor: A Potential Therapeutic Agent for the Treatment of Hepatitis C Infection

Published:2006-09-07 Issue:20 Volume:49 Page:6074-6086
ISSN:0022-2623
Container-title:Journal of Medicinal Chemistry
language:en
Short-container-title:J. Med. Chem.

Author:

Venkatraman Srikanth¹,Bogen Stéphane L.¹,Arasappan Ashok¹,Bennett Frank¹,Chen Kevin¹,Jao Edwin¹,Liu Yi-Tsung¹,Lovey Raymond¹,Hendrata Siska¹,Huang Yuhua¹,Pan Weidong¹,Parekh Tejal¹,Pinto Patrick¹,Popov Veljko¹,Pike Russel¹,Ruan Sumei¹,Santhanam Bama¹,Vibulbhan Bancha¹,Wu Wanli¹,Yang Weiying¹,Kong Jianshe¹,Liang Xiang¹,Wong Jesse¹,Liu Rong¹,Butkiewicz Nancy¹,Chase Robert¹,Hart Andrea¹,Agrawal Sony¹,Ingravallo Paul¹,Pichardo John¹,Kong Rong¹,Baroudy Bahige¹,Malcolm Bruce¹,Guo Zhuyan¹,Prongay Andrew¹,Madison Vincent¹,Broske Lisa¹,Cui Xiaoming¹,Cheng Kuo-Chi¹,Hsieh Yunsheng¹,Brisson Jean-Marc¹,Prelusky Danial¹,Korfmacher Walter¹,White Ronald¹,Bogdanowich-Knipp Susan¹,Pavlovsky Anastasia¹,Bradley Prudence¹,Saksena Anil K.¹,Ganguly Ashit¹,Piwinski John¹,Girijavallabhan Viyyoor¹,Njoroge F. George¹

Affiliation:

1. Schering Plough Research Institute, K-15, 2015 Galloping Hill Road, Kenilworth New Jersey 07033

Publisher

American Chemical Society (ACS)

Subject

Drug Discovery,Molecular Medicine

Link

https://pubs.acs.org/doi/pdf/10.1021/jm060325b

Reference50 articles.

1. Epidemiology of Hepatitis C: Geographic Differences and Temporal Trends

2. Scope of worldwide hepatitis C problem

3. Interferon Alfa-2b Alone or in Combination with Ribavirin as Initial Treatment for Chronic Hepatitis C

4. Interferon Alfa-2b Alone or in Combination with Ribavirin for the Treatment of Relapse of Chronic Hepatitis C

Cited by 259 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Hepatitis C: The Story of a Long Journey through First, Second, and Third Generation NS3/4A Peptidomimetic Inhibitors. What Did We Learn?;Journal of Medicinal Chemistry;2024-01-05

2. On the origins of SARS-CoV-2 main protease inhibitors;RSC Medicinal Chemistry;2024

3. Synthesis of Nirmatrelvir: Development of a Scalable Cobalt-Catalyzed Cyclopropanation for Manufacture of the Bicyclic [3.1.0]Proline-Building Block;Organic Process Research & Development;2023-12-04

4. Molecules for COVID-19 treatment;Chinese Chemical Letters;2023-12

5. Structure–Activity Relationship Studies of SARS-CoV-2 Main Protease Inhibitors Containing 4-Fluorobenzothiazole-2-carbonyl Moieties;Journal of Medicinal Chemistry;2023-09-27